ClinicalTrials.gg
CompletedNCT05960240Updated Apr 13, 2026

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

A Phase 1 interventional study of AB-101 and Placebo in Chronic Hepatitis b, sponsored by Arbutus Biopharma Corporation. Completed at 10 sites in 7 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Arbutus Biopharma Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Hepatitis B, Chronic with a site in Hong Kong — 9 open to participants now, 15 under way, none of them phase 3. Hepatitis B, Chronic · Hong Kong.

Enrollment
33rd of 79
128 · median 114
Started
2023
with 4 others
Phase 1
22 of 88
4 open now
Registered
76th of 88
by date
Lead sponsor
3 of 88
Arbutus Biopharma Corporation

Among the 88 studies in Hepatitis B, Chronic with a site in Hong Kong, this one is the 33rd largest by enrollment of the 79 interventional ones that give a count, is one of 5 that started in 2023, is one of 22 in phase 1, and was the 76th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

9 of the 88 studies in Hepatitis B, Chronic with a site in Hong Kong are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Hepatitis B, Chronic with a site in Hong Kong, or all of them as a file.
02

Study summary

This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects.

Part 3 will be a Phase 1b dose-ranging assessment of AB-101 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.

03

Conditions studied

  • Chronic Hepatitis b

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Part 1 and 2 (Healthy Volunteers)

  • Male between ages 18-50 years
  • Willing and able to provide

Willing to follow protocol-specified requirement

Inclusion Criteria: Part 3 (CHB Subjects)

  • Male or female subjects between the ages of 18-60 years
  • Willing to provide informed consent
  • Chronic infection for at least 6 months
  • Willing to follow protocol-specified contraception requirement

Exclusion Criteria: Part 1 and 2 (Healthy Volunteers)

Key Exclusion Criteria:

  • lab abnormalities
  • A history of clinically significant gastrointestinal, hematologic, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, or other immune-mediated disease.
  • or Hep C positive
  • Known chronic or severe infection or recent significant exposure to infections such as tuberculosis or endemic mycosis, untreated latent infections like tuberculosis, or a positive or indeterminate QuantiFERON test.

Exclusion Criteria: Part 3 (CHB Subjects)

  • Have extensive fibrosis or cirrhosis of the liver
  • Have or had liver cancer (hepatocellular carcinoma)
  • Have a history or current autoimmune disease or has been on medications within 6 months of the start of the study
  • Females who breastfeeding, pregnant or who wish to become pregnant during the study
  • Known chronic or severe infection or recent significant exposure to infections such as tuberculosis or endemic mycosis, untreated latent infections like tuberculosis, or a positive or indeterminate QuantiFERON test.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Part 1

    Drug: AB-101 · Drug: Placebo

  • Experimental
    Part 2

    Drug: AB-101 · Drug: Placebo

  • Experimental
    Part 3

    Drug: AB-101 · Drug: Placebo · Drug: Nucleos(t)ide Analogue

Interventions

  • DrugAB-101

    AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.

  • DrugPlacebo

    A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.

  • DrugNucleos(t)ide Analogue

    Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Incidence of adverse events (AEs), serious AEs (SAEs), immune related AEs (irAEs) and discontinuations due to AEs and irAEs.

    Time frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]

  2. Part 3: Incidence of AEs, SAEs, irAEs and discontinuations due to AEs and irAEs

    Time frame: [Time Frame: Up to 196 days]

  3. Parts 1 and 2: Incidence of clinically significant laboratory abnormalities Parts 1 and 2: Incidence of clinically significant laboratory abnormalities

    Time frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]

  4. Parts 1 and 2: Incidence of clinically significant changes in vital signs (heart rate, blood pressure, temperature, respiratory rate), physical examinations and electrocardiograms (ECGs)

    Time frame: [Time Frame: Up to 57 (Part 1) or 84 (Part 2) days]

  5. Part 3: Incidence of clinically significant laboratory abnormalities

    Time frame: [Time Frame: Up to 196 days]

  6. Part 3: Incidence of clinically significant changes in vital signs (heart rate, blood pressure, temperature, respiratory rate), physical examinations and electrocardiograms (ECGs)

    Time frame: [Time Frame: Up to 196 days]

07

Study locations

10 sites
  • Prince of Wales Hospital
    Hong Kong, Hong Kong, Hong Kong
  • Queen Mary Hospital - PPDS
    Hong Kong, Hong Kong, Hong Kong
  • ASST Papa Giovanni XXIII -Osepedale
    Bergamo, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milan, Italy
  • Clinial Republican Hospital "Timofei Mosneaga"
    Chisinau, Moldova
  • New Zealand Clinical Research Auckland
    Grafton, Auckland, New Zealand
  • Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E. M.
    Bucharest, Romania
  • National University Hospital
    Singapore, Singapore
  • Singapore General Hospital
    Singapore, Singapore
  • Municipal Non-Profit Enterprise Kyiv City Clinical Hospital No12 Executive Body of Kyiv City Council
    Kyiv, Ukraine
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Dec 2025, 27 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 27 months is above that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2023
First posted
Jul 25, 2023
StartActual
Aug 30, 2023
Primary completionActual
Dec 4, 2025
CompletionActual
Feb 9, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05960240
Lead sponsor
Arbutus Biopharma Corporation
Responsible party
Sponsor
First posted
Jul 25, 2023
Start date
Aug 30, 2023
Primary completion
Dec 4, 2025
Completion
Feb 9, 2026
Last update
Apr 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AB-101

Start the discussion